Silex Systems Limited (SILXY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Silex Systems Limited (SILXY) trades at $18.98 with AI Score 45/100 (Grade C). Silex Systems Limited focuses on developing and commercializing its SILEX laser uranium enrichment technology and cREO technology. Market cap: $904.40M, Sector: Technology.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SILXY: SILXY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SILXY against Technology peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SILXY: the 1 perspectives are evenly split.
How is this calculated? →Silex Systems Limited (SILXY) Technology Profile & Competitive Position
Silex Systems Limited, an Australian technology company, specializes in SILEX laser uranium enrichment and cREO technologies. Operating within the semiconductor industry, the company focuses on research, development, and commercialization, distinguishing itself through its unique laser enrichment technology and integration solutions for compound semiconductor devices.
What Is the Investment Thesis for SILXY?
Silex Systems Limited presents a speculative investment opportunity centered on the successful commercialization of its SILEX laser uranium enrichment technology. The company's negative P/E ratio of -33.19 and a negative profit margin of -309.4% indicate it is not currently profitable. The key value driver is the potential licensing revenue from its SILEX technology, particularly through its partnership with Cameco. Upcoming catalysts include advancements in the commercial deployment of the SILEX technology at the Paducah, Kentucky facility. Potential risks include delays in technology deployment, competition from established uranium enrichment methods, and the company's current lack of profitability.
Based on FMP financials and quantitative analysis
SILXY Key Highlights
- Market capitalization of $904.40M reflects investor expectations regarding the future potential of Silex Systems' technologies.
- Negative P/E ratio of -33.19 indicates the company is currently unprofitable, primarily due to ongoing research and development expenses.
- Gross margin of 2.3% highlights the early stage of commercialization and the high costs associated with technology development.
- Beta of 0.22 suggests the stock is significantly less volatile than the overall market.
- Strategic partnership with Cameco Corporation provides a pathway for commercializing the SILEX laser uranium enrichment technology.
Who Are SILXY's Competitors?
SILXY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASAAF AT & S Austria Technologie & Systemtechnik AG | $223.40 | +3.23% | $13.69B | 49 |
| ASMVY ASMPT Limited | $75.35 | +2.28% | $3.51B | 56 |
| ATEAY Atea ASA | $8.89 | +0.00% | $1.98B | 45 |
| AUKUF ams-OSRAM AG | $20.84 | +1.91% | $2.06B | 47 |
| DLGEF Digital Garage, Inc. | $17.54 | +0.00% | $806.82M | 57 |
| ARM Arm Holdings plc American Depositary Shares | $322.82 | +2.39% | $343.48B | 72 |
| MRVL Marvell Technology, Inc. | $252.03 | +2.75% | $220.47B | 69 |
| SLAB Silicon Laboratories Inc. | $218.46 | +0.11% | $7.21B | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SILXY's Key Strengths?
- Proprietary SILEX laser uranium enrichment technology.
- Unique cREO technology for semiconductor integration.
- Strategic partnership with Cameco Corporation.
- Strong focus on research and development.
What Are SILXY's Weaknesses?
- Currently unprofitable with negative profit margins.
- Reliance on successful commercialization of its technologies.
- Small number of employees and limited resources.
- Dependence on strategic partnerships for commercialization.
What Could Drive SILXY Stock Higher?
- Progress in the development and deployment of SILEX laser uranium enrichment technology at the Paducah facility.
- Potential licensing agreements with other uranium producers.
- Advancements in cREO technology for semiconductor applications.
- Securing government funding and grants for research and development.
- Development of new applications for SILEX technology beyond uranium enrichment.
What Are the Key Risks for SILXY?
- Negative return on equity (-27.5%) — the business is not currently generating profit on shareholder capital.
- Delays in technology deployment and commercialization.
- Competition from established uranium enrichment technologies.
- Technological obsolescence.
- Economic and political instability.
- Limited financial disclosure and liquidity risks associated with trading on the OTC market.
What Are the Growth Opportunities for SILXY?
- Commercialization of SILEX Technology: Silex Systems' primary growth opportunity lies in the successful commercialization of its SILEX laser uranium enrichment technology. The global uranium enrichment market is estimated to be worth billions of dollars annually. The timeline for significant revenue generation depends on the successful deployment of the technology at the Paducah facility, with potential for licensing agreements with other uranium producers. Silex's competitive advantage is its potentially lower cost and higher efficiency compared to traditional enrichment methods.
- Expansion of cREO Technology Applications: The development and application of cREO technology offer another growth avenue. This technology enables the integration of compound semiconductors with silicon, which is crucial for advanced microelectronics and photonics. The market for advanced semiconductor materials is growing rapidly, driven by demand for faster and more efficient devices. Silex's competitive advantage is its unique approach to integrating dissimilar materials, potentially leading to higher-performance devices.
- Strategic Partnerships and Licensing Agreements: Silex Systems can pursue growth through strategic partnerships and licensing agreements with companies in the nuclear fuel and semiconductor industries. These partnerships can provide access to capital, expertise, and established markets. The timeline for these partnerships depends on the progress of technology development and validation. Silex's competitive advantage is its proprietary technology and its potential to disrupt established markets.
- Government Funding and Grants: Silex Systems can leverage government funding and grants to support its research and development activities. Governments around the world are investing in advanced technologies for energy and microelectronics. Securing these grants can provide non-dilutive funding and accelerate technology development. The timeline for securing funding depends on the availability of grants and the competitiveness of Silex's proposals. Silex's competitive advantage is its innovative technology and its potential to address critical national needs.
- Development of New Applications for SILEX Technology: Silex Systems can explore new applications for its SILEX technology beyond uranium enrichment. The technology's unique properties may be applicable to other areas, such as isotope separation for medical or industrial purposes. The timeline for developing these new applications depends on the success of research and development efforts. Silex's competitive advantage is its deep understanding of laser isotope separation and its ability to adapt the technology to new challenges.
What Opportunities Does SILXY Have?
- Growing demand for efficient uranium enrichment methods.
- Expanding market for advanced semiconductor materials and integration techniques.
- Potential for government funding and grants.
- Development of new applications for SILEX technology.
What Threats Does SILXY Face?
- Competition from established uranium enrichment technologies.
- Delays in technology deployment and commercialization.
- Technological obsolescence.
- Economic and political instability.
What Are SILXY's Competitive Advantages?
- Proprietary SILEX laser uranium enrichment technology.
- Unique cREO technology for integrating compound semiconductors with silicon.
- Strategic partnership with Cameco Corporation.
- Intellectual property protection through patents and trade secrets.
What Does SILXY Do?
Silex Systems Limited, founded in 1987 and headquartered in Sydney, Australia, is a technology company focused on the research, development, and commercialization of its proprietary SILEX laser uranium enrichment technology. This technology aims to provide a more efficient and cost-effective method for uranium enrichment compared to traditional methods. Additionally, Silex Systems is developing cREO (crystalline Rare Earth Oxide) technology, which facilitates the integration of compound semiconductor devices with silicon wafer-based production techniques. This technology has potential applications in various industries, including microelectronics and photonics. The company's primary focus is on licensing its SILEX technology to strategic partners for deployment in uranium enrichment facilities. Silex has a strategic relationship with Cameco Corporation, a major uranium producer, to commercialize the SILEX technology. The company's operations are primarily based in Australia, with a focus on global licensing and commercialization opportunities. Silex Systems operates with a relatively small team of 38 employees, emphasizing its focus on research and development rather than large-scale manufacturing.
What Products and Services Does SILXY Offer?
- Researches and develops SILEX laser uranium enrichment technology.
- Seeks to commercialize and license the SILEX technology to uranium producers.
- Develops cREO technology for integrating compound semiconductors with silicon.
- Aims to improve the efficiency and cost-effectiveness of uranium enrichment.
- Focuses on licensing its technologies rather than large-scale manufacturing.
- Collaborates with strategic partners like Cameco Corporation.
How Does SILXY Make Money?
- Generates revenue through licensing agreements for its SILEX laser uranium enrichment technology.
- Potential revenue from the development and licensing of cREO technology.
- Partnerships with companies in the nuclear fuel and semiconductor industries.
- Government funding and grants for research and development activities.
What Industry Does SILXY Operate In?
Silex Systems operates in the technology sector, specifically within the semiconductor and nuclear fuel industries. The uranium enrichment market is dominated by established technologies like gas centrifuges, but there is ongoing demand for more efficient and cost-effective enrichment methods. The semiconductor industry is characterized by rapid innovation and increasing demand for advanced materials and integration techniques. Silex's cREO technology targets this demand by enabling the integration of compound semiconductors with silicon-based manufacturing. Competitors include companies involved in uranium enrichment and semiconductor materials development.
Who Are SILXY's Key Customers?
- Uranium producers seeking more efficient enrichment methods.
- Semiconductor manufacturers looking to integrate compound semiconductors with silicon.
- Strategic partners in the nuclear fuel and semiconductor industries.
- Government agencies and research institutions.
ROE -28%Key Financial Metrics
Return on equity for Silex Systems Limited stands at -27.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 31.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.
Silex Systems Limited (SILXY) Valuation Context
Valued at $904.40M, SILXY is classified as a small-cap stock. Relative to its peer group, SILXY's quantitative score of 45/100 is roughly in line with the peer average of 51/100.
Company Profile
Silex Systems Limited operates in the Semiconductors industry within the Technology sector. It is headquartered in Sydney, AU. The company is led by CEO Michael Goldsworthy. SILXY has traded publicly since 2007.
F-Score 5/9Financial Health
Silex Systems Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
FY2026 estForward Outlook
Wall Street analysts project Silex Systems Limited revenue of about $7.5M for fiscal 2026, with EPS near $-0.41.
SILXY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary SILEX laser uranium enrichment technology.
- Unique cREO technology for semiconductor integration.
- Strategic partnership with Cameco Corporation.
- Strong focus on research and development.
Bear Case
- Currently unprofitable with negative profit margins.
- Reliance on successful commercialization of its technologies.
- Small number of employees and limited resources.
- Dependence on strategic partnerships for commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SILXY Latest News
No recent news available for SILXY.
SILXY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SILXY.
Price Targets
Wall Street price target analysis for SILXY.
SILXY MoonshotScore
What does this score mean?
The MoonshotScore rates SILXY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Goldsworthy
CEO
Michael Goldsworthy serves as the CEO of Silex Systems Limited, managing a team of 38 employees. His background includes extensive experience in technology commercialization and strategic partnerships. He has been instrumental in guiding Silex Systems through its research and development phases, focusing on the commercial application of its SILEX laser uranium enrichment technology and cREO technology. His leadership is focused on securing strategic alliances and navigating the regulatory landscape for technology deployment.
Track Record: Under Michael Goldsworthy's leadership, Silex Systems has advanced the development of its SILEX technology and secured a strategic partnership with Cameco Corporation. Key milestones include the progression of the Paducah, Kentucky, project and the ongoing development of cREO technology for semiconductor applications. His tenure has been marked by a focus on innovation and the pursuit of commercial opportunities for Silex's technologies.
Silex Systems Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SILXY is an ADR representing shares of Silex Systems Limited, allowing U.S. investors to invest in the Australian company without directly dealing with foreign exchanges. It simplifies trading and reduces complexities associated with international investing.
- Home Market Ticker: Australian Securities Exchange (ASX), Australia
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SILX
SILXY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. This contrasts sharply with NYSE/NASDAQ listings, which demand rigorous financial reporting and corporate governance standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in SILXY.
- Low trading volume and wide bid-ask spread can make it difficult to buy or sell the stock.
- Potential for fraud or manipulation on the OTC market.
- Lack of regulatory oversight compared to major exchanges.
- Higher price volatility due to limited liquidity and disclosure.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in the OTC market.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or investigations involving the company.
- Confirm the legitimacy of the company's operations and assets.
- Established business operations in Australia.
- Partnership with Cameco Corporation, a major uranium producer.
- Development of proprietary technologies.
- Presence on the OTC market as an ADR, indicating some level of compliance with U.S. regulations.
Silex Systems Limited Technology Stock: Key Questions Answered
What does Silex Systems Limited do?
Silex Systems Limited is a technology company focused on the development and commercialization of its proprietary SILEX laser uranium enrichment technology and cREO technology. The SILEX technology aims to provide a more efficient and cost-effective method for uranium enrichment, while the cREO technology facilitates the integration of compound semiconductor devices with silicon wafer-based production techniques. The company primarily generates revenue through licensing agreements and strategic partnerships.
What do analysts say about SILXY stock?
As an ADR traded on the OTC market, SILXY may have limited analyst coverage. Key valuation metrics include its market capitalization of $904.40M and negative P/E ratio of -33.19. Growth considerations center on the successful commercialization of its SILEX technology and the expansion of its cREO technology applications. Investors should conduct their own due diligence and consider the risks associated with investing in an OTC-traded stock.
What are the main risks for SILXY?
The main risks for SILXY include delays in technology deployment and commercialization, competition from established uranium enrichment technologies, technological obsolescence, and economic and political instability. Additionally, the limited financial disclosure and liquidity risks associated with trading on the OTC market pose significant challenges for investors. Currency risk is also a factor due to its status as an ADR.
What are the key factors to evaluate for SILXY?
Silex Systems Limited (SILXY) holds an AI score of 45/100 (low). Not financial advice.
How frequently does SILXY data refresh on this page?
SILXY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SILXY's recent stock price performance?
Silex Systems Limited (SILXY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SILEX laser uranium enrichment technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SILXY overvalued or undervalued right now?
Valuing Silex Systems Limited (SILXY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SILXY?
Before investing in Silex Systems Limited (SILXY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available financial data and company descriptions.
- OTC market data may be limited and subject to inaccuracies.